Parviz Amri Maleh - Clinical Research Development Unit of Ayatollah Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran
Kayvan Latifi - Specialty student of Critical Care Medicine, Department of Anesthesiology, School of Medicine, Babol University of Medical Sciences
Shahram Seyfi - Clinical Research Development Unit of Ayatollah Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran
Khadijeh Ezoji - Social Determinants of Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran

SARS-CoV-۲ (COVID-۱۹) is an infectious disease caused by a new discovered Coronavirus. Most people infected with the COVID-۱۹ virus recover without special treatment and experience mild to moderate respiratory disease. In the elderly and people with underlying diseases such as cardiovascular disease, diabetes, chronic respiratory disease and cancer, there is a higher risk of developing the severe form of the disease. So far, no specific drug has been found to prevent or treat COVID-۱۹. A ۵۲-years old diabetic man with COVID-۱۹ was admitted to Ayatollah Rouhani Hospital Babol, Iran. After ۱۲ days of hospitalization and treatment, with respiratory distress and oxygen saturation level to ۶۰%, he was transferred to the intensive care unit. After receiving a ۴۰۰ mg dose of actemra or tocilizumab, the patient became severely dehydrated and the oxygen saturation level reached over ۹۰% within a few hours, and ۸ days after receiving tocilizumzb (TCZ; Actemra), the patient was suffering from complications of pneumonia. So far, there have been reports of improvement in patients with Coronavirus (COVID-۱۹) with severe actemra or tocilizumab. Typically the COVID-۱۹ virus appears to be able to be cause the over-immune reaction and typically the cytokine storm, which often includes IL-۶, therefor may be IL-۶ antagonist improves patients’s condition.

COVID-۱۹; Actemra; Tocilizumab